Studies heart and kidney outcomes in chronic kidney disease with heart failure
Observes adults with kidney disease and heart failure, some taking SGLT2 inhibitors.
Plain-language title generated from the registry record
Registry title: Cardiovascular and Renal Endpoints With Flozins - an Observational Prospective Study in CKD HFpEF Patients
Key facts
- Where
- Iași, RomaniaSee the site
Where in Romania
- Dr. C.I. Parhon Hospital in IasiIași, RomaniaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Grigore T. Popa University of Medicine and Pharmacy
- Trial code
- NCT07237451
- Record updated
- 19 November 2025
- Original description
The main aim of this study is to holistically assess the cardiovascular and renal outcomes in HFpEF CKD patients with and without SGLT2 inhibition, with focus on the endothelial disfunction, MACE and mortality using clinical evaluation, flow mediated dilatation, carotid-femoral pulse wave velocity, intima-media thickness, echocardiographic parameters, NMR metabolomics and a series of novel biomarkers.Read full original descriptionShow less
Cardiovascular and Renal Endpoints With Flozins - an Observational Prospective Study in CKD HFpEF Patients
The main aim of this study is to holistically assess the cardiovascular and renal outcomes in HFpEF CKD patients with and without SGLT2 inhibition, with focus on the endothelial disfunction, MACE and mortality using clinical evaluation, flow mediated dilatation, carotid-femoral pulse wave velocity, intima-media thickness, echocardiographic parameters, NMR metabolomics and a series of novel biomarkers.
Inclusion: age>18 years; ejection fraction > 40; patients with CKD stage 3-4 (eGFR between 15-60 mL/min/1.73m2), with iSGLT2 recommendation, diabetic and non-diabetic; age, sex and CKD stage 3 and 4 matched patients without iSGLT2 administration.
Exclusion: coronary artery disease (including those with a history of acute coronary syndrome, angina pectoris, or prior coronary angiography or CT angiography demonstrating significant coronary artery lesions); presence of congenital heart disease, decompensated cirrhosis, pregnancy and active malignancies; cardiac medical devices, namely metallic joint prostheses, cardiac stent or pacemakers; active systemic infections (due to interference with biomarkers that can give false rise values); eGFR< 15 mL/min/1.73m2 or patients undergoing dialysis.